ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Amphotericin B nephrotoxicity

Amphotericin B nephrotoxicity
Literature review current through: Jan 2024.
This topic last updated: May 17, 2023.

INTRODUCTION — Amphotericin B is used in the treatment of often life-threatening fungal infections. Acute kidney injury (AKI) is a relatively common complication of amphotericin B deoxycholate, as are other kidney manifestations, including urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA), and polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus). Lipid-based formulations of amphotericin B have reduced but not completely eliminated the risk of nephrotoxicity.

An overview of amphotericin B nephrotoxicity is presented here. The management of hypokalemia, hypomagnesemia, distal RTA, and AVP-R is discussed in detail elsewhere:

(See "Clinical manifestations and treatment of hypokalemia in adults", section on 'Treatment'.)

(See "Hypomagnesemia: Evaluation and treatment".)

(See "Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) renal tubular acidosis'.)

(See "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment".)

ACUTE KIDNEY INJURY

Incidence and risk factors — Acute kidney injury (AKI) is a common complication of conventional amphotericin B (ie, amphotericin B deoxycholate) [1-6]. In the two largest reviews, a 50 percent or greater increase in serum creatinine was observed in 138 of 494 and 174 of 643 patients (28 and 27 percent, respectively) [4,5]. The incidence of nephrotoxicity is lower with lipid-based formulations of amphotericin B, as discussed below. (See 'Use of lipid-based formulations' below.)

The risk of amphotericin-induced kidney injury is influenced by other factors:

Concurrent therapy with other nephrotoxins, such as an aminoglycoside, cyclosporine, or foscarnet, increases the risk of AKI [4-7]. In one report, the incidence of a twofold or greater increase in serum creatinine was 15 percent in patients taking no or one concurrent nephrotoxic drug and 41 percent in those taking two or more concurrent nephrotoxic drugs [6].

Chronic kidney disease (CKD) at baseline and the severity of the underlying illness also increase the risk [4,5]. In one series, the incidence of moderate to severe nephrotoxicity (defined as a doubling of the serum creatinine to a level greater than 2 mg/dL) was 4 percent in patients with no risk factors for AKI and 8 to 29 percent in those with CKD [4].

The likelihood of kidney disease is also dose dependent, with the risk of kidney function impairment being low at doses of less than 0.5 mg/kg per day and a cumulative dose of less than 600 mg [4,5,7].

A prediction rule risk stratified patients based upon the following clinical data available during the course of therapy: location of care (general medical unit versus intensive care unit), concurrent use of cyclosporine, and maximum daily amphotericin B dose (<60 mg versus ≥60 mg daily). In the lowest risk group (12 percent of patients), the risk of nephrotoxicity was 4 percent, while in the highest risk group (10 percent of patients), the risk of AKI was 80 percent [5].

Pathogenesis of AKI — The original formulation of amphotericin B contains sodium deoxycholate to increase the solubility of amphotericin B in water. The hydrophobic part of the molecule binds to ergosterol, the main sterol in the cytoplasmic membrane of fungi. This forms pores and channels in the plasma membrane that allow the extravasation of electrolytes from the intracellular medium (such as potassium, ammonium, and phosphate) in addition to carbohydrate and proteins, thereby causing cell death. Besides its affinity for the fungal ergosterol, amphotericin B deoxycholate also has affinity for cholesterol present in mammalian cells. Thus, in addition to its antifungal activity, amphotericin B causes substantial toxicity to mammalian cells, causing kidney, heart, and hematologic injury [8-11].

Proximal tubular cells and medullary interstitial cells respond with programmed cell death when treated with therapeutic doses of amphotericin B. In animal models, the number of apoptotic tubular cells correlates with the degree of hypokalemia and loss of renal concentrating ability; administration of insulin-like growth factor-1, an antiapoptotic agent, prevents hypokalemia and preserves concentrating ability [12]. In addition to this direct effect, in vitro studies suggest that approximately one-half of the tubular toxicity of amphotericin B may be mediated by deoxycholate [8-11].

The reduction in glomerular filtration rate (GFR) associated with amphotericin B-induced tubular toxicity may be mediated in part by the tubuloglomerular feedback (TGF) system [1,13]. Normally, when sodium chloride delivery to the distal tubule increases, a greater quantity of sodium chloride enters the macula densa cells located in the early portion of the distal tubule. This results in activation of a feedback loop (TGF), which triggers afferent arteriolar vasoconstriction and a fall in GFR [1,13]. Under most circumstances, this TGF response is physiologically appropriate: high rates of sodium chloride delivery out of the proximal tubule are restored to near normal levels by the appropriate reduction in GFR, and this prevents excessive sodium chloride losses in the urine [14]. However, amphotericin B nephrotoxicity increases the permeability of the macula densa cells. This may inappropriately activate the TGF system and lead to excessive afferent arteriolar vasoconstriction and a fall in GFR [1,13].

Alternatively, the renal vasoconstriction and fall in GFR may reflect a direct action of amphotericin B on blood vessels, rather than TGF [15]. In experimental animals, administration of a calcium channel blocker prevents amphotericin-induced vasoconstriction and the resultant decline in GFR [16].

Clinical presentation — Amphotericin B-associated AKI generally manifests with an increase in serum creatinine at four to five days following drug initiation, while hypokalemia and hypomagnesemia develop within or slightly after (seven to eight days) that time frame. However, these nephrotoxic events may occur before or after the noted times [17,18]. (See 'Electrolyte and acid-base disorders' below.)

In most cases, the serum creatinine increases by no more than 2.5 mg/dL (220 micromol/L) above baseline [1,4,5,13]. More severe kidney injury due to amphotericin B alone is uncommon but can occur with diuretic-induced volume depletion or the concurrent administration of another nephrotoxin.

The nephrotoxicity associated with amphotericin B is usually reversible with discontinuation of therapy [13,19]. However, recurrent AKI can occur if treatment is reinstituted [19]. There are no data on the long-term clinical course of patients following amphotericin B-associated AKI.

Monitoring — All patients receiving amphotericin B should be monitored for nephrotoxicity during therapy, particularly those with underlying risk factors. Electrolytes, blood urea nitrogen (BUN), and serum creatinine along with serum magnesium concentrations should be measured while on therapy with amphotericin B. (See 'Incidence and risk factors' above.)

Prevention — The risk of nephrotoxicity can be reduced by using lower doses of amphotericin and by avoiding concurrent therapy with other nephrotoxins, such as an aminoglycoside or cyclosporine [4,5]. Two other preventive measures are salt loading and the use of lipid formulations of amphotericin B. In addition, for some fungal infections, non-amphotericin B agents are now available.

Salt loading — For patients who are going to receive amphotericin B (conventional or lipid-based formulation) and who are not hypervolemic, we suggest volume expansion with isotonic fluids (typically isotonic saline) rather than more dilute fluids or no volume expansion to prevent the development of AKI. In patients who are euvolemic, a total of 500 mL of isotonic saline is typically given immediately prior to the amphotericin B infusion or divided before and after amphotericin B administration. Patients who are hypovolemic may require additional isotonic saline for volume repletion, while those who are hypervolemic should not receive isotonic saline prior to or after receiving amphotericin B.

The proposed importance of TGF in amphotericin B nephrotoxicity has led to the use of salt loading since volume expansion has been shown to reduce the sensitivity of the TGF system. Studies in both humans and animals have shown that saline administration can protect against or ameliorate the amphotericin B-induced decline in GFR [1,2,13,20] but not the signs of tubular dysfunction described above [20]. (See 'Pathogenesis of AKI' above.)

The beneficial effect of salt loading was best shown in a controlled study of patients with mucocutaneous leishmaniasis who received a 10-week course of amphotericin B (average dose 50 mg per day, given three times per week) [20]. The serum creatinine concentration was stable with salt loading (1 liter of isotonic saline over the 60 minutes prior to amphotericin B administration) but rose from 0.6 to 1 mg/dL (53 to 88 micromol/L) in patients given only water. The minor degree of kidney function impairment in the relatively healthy control group probably reflects in part the absence of potentiating factors, such as volume depletion or concurrent aminoglycoside therapy.

However, this benefit of salt loading does not prove that TGF, rather than vasoconstriction, is the major mechanism underlying the reduced GFR. Increases in the secretion of vasoconstrictors (angiotensin II and norepinephrine) and decreases in the secretion of the vasodilator atrial natriuretic peptide might modulate the constrictive effect of amphotericin B [15]; volume expansion could prevent these hormonal changes.

Use of lipid-based formulations — Administering amphotericin B in a lipid-based formulation can minimize, though not eliminate, the incidence and severity of nephrotoxicity. Two lipid-based amphotericin B formulations are available: amphotericin B lipid complex (ABLC) and liposomal amphotericin B (L-AMB). These formulations have largely supplanted the use of amphotericin B deoxycholate in resource-abundant countries. L-AMB may be less nephrotoxic than ABLC [21]. (See "Pharmacology of amphotericin B", section on 'Lipid-based amphotericin B formulations'.)

Data from randomized trials [22-24] and observational studies [25-28] suggest that administering amphotericin B in a lipid-based formulation can minimize, though not eliminate, the incidence and severity of nephrotoxicity. The best comparative data are reported in a meta-analysis of randomized trials that compared conventional amphotericin B with both liposomal amphotericin B (five trials, 1233 patients) and lipid emulsion amphotericin B (nine trials, 459 patients) [22]. Compared with conventional amphotericin B, the incidence of nephrotoxicity was reduced with the use of liposomal amphotericin B (15 versus 33 percent) or lipid emulsion amphotericin B (12 versus 31 percent).

The reason why lipid-based formulations are associated with less AKI is incompletely understood. However, two possibilities have been proposed:

The liposomal preparation does not contain deoxycholate, which (as noted above) has direct tubular toxicity [8]. (See 'Pathogenesis of AKI' above.)

The liposomes may be preferentially distributed to the reticuloendothelial system, where amphotericin B can be transferred directly to trapped fungi with less delivery to other cholesterol-containing cells, such as those in the kidney [9].

As with amphotericin B deoxycholate, the risk of nephrotoxicity with lipid-based formulations is higher among patients concurrently treated with other potentially nephrotoxic drugs, including aminoglycosides, cyclosporine, foscarnet, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) [6,27,29,30].

Preventive interventions of unclear benefit — N-acetylcysteine has been shown to protect against amphotericin-induced nephrotoxicity in animal models, preserving GFR and reducing apoptosis of renal tubular cells [31,32]. Evidence for a protective role in humans, however, has been inconclusive [33].

Pentoxifylline and sodium bicarbonate have also been employed for prophylaxis without success [17,34].

Continuous infusion of amphotericin B deoxycholate over 24 hours may help to minimize potentially nephrotoxic peak concentrations and decrease nephrotoxicity when compared with conventional infusion (over two to six hours) [35-37]. There are no studies comparing this approach with the use of lipid-based formulations of amphotericin B.

Management of AKI — For patients with amphotericin B-associated AKI, discontinuing amphotericin B and switching to another effective antifungal agent is appropriate. The general approach to the management of AKI after amphotericin administration is the same as that for other causes of AKI. These issues are discussed separately. (See "Overview of the management of acute kidney injury (AKI) in adults" and "Prevention and management of acute kidney injury (acute renal failure) in children".)

ELECTROLYTE AND ACID-BASE DISORDERS — Amphotericin B has been associated with the following electrolyte and acid-base disorders:

Urinary potassium wasting and hypokalemia

Urinary magnesium wasting and hypomagnesemia

Metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA)

Polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus)

Pathogenesis — The increase in membrane permeability caused by amphotericin B is also thought to contribute to the electrolyte abnormalities that often occur. This defect results in the reduction of ion concentration gradients, which normally exist between the cytoplasm of distal tubule cells and the tubule lumen. In these cases, potassium leaks from the cytoplasm down a favorable concentration gradient into the lumen. Similarly, hydrogen ions diffuse down their gradient from the lumen into the cytoplasm of distal tubule cells [38]. Thus, an increase in tubular permeability will promote the back-diffusion of secreted hydrogen ions (or of carbonic acid formed by the combination of hydrogen with filtered bicarbonate), thereby limiting acid excretion [39-41]. Hypomagnesemia and renal magnesium wasting also occur as a result of amphotericin kidney toxicity [41,42].

The loss of magnesium and potassium may also be related in part to the systemic toxicity of the amphotericin B that causes these intracellular ions to leak into the extracellular fluid space and then be lost into the urine [2].

The net effect of these changes is that both hypokalemia due to potassium loss and a normal anion gap metabolic acidosis (ie, a distal RTA) due to hydrogen retention are commonly seen [2,6,38,40]. Hypomagnesemia, though somewhat less common, is also reported. The distal RTA generated by amphotericin B, unlike most other forms of distal RTA, is associated with a normal urine-blood partial pressure of carbon dioxide (PCO2) after alkaline loading [43,44]. This likely results from the previously mentioned back-diffusion of secreted hydrogen ions, but a loss of polarity of the chloride-bicarbonate exchanger is also consistent with this finding [43].

Amphotericin B may also cause resistance to antidiuretic hormone, leading to polyuria and polydipsia [2,6,44,45]. (See "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes".)

Prevention and management

Prevention – As with acute kidney injury (AKI), the use of liposomal amphotericin B may help to prevent electrolyte abnormalities and AVP-R [6,46]. In one randomized trial, patients receiving liposomal amphotericin B had a significantly lower rate of hypokalemia (serum potassium concentration ≤2.5 mEq/L) but no significant change in the rate of hypomagnesemia (serum magnesium concentration ≤1.5 mg/dL [0.6 mmol/L]) [6]. (See 'Use of lipid-based formulations' above.)

If conventional amphotericin B is used, patients without significant kidney function impairment should receive daily preemptive administration of potassium, which may prevent serious hypokalemia due to urinary potassium wasting [47].

In contrast to AKI, amphotericin B-induced electrolyte and acid-base abnormalities do not appear to be ameliorated by volume expansion [20]. (See 'Salt loading' above.)

Management – In general, treatment of the hypokalemia and RTA consists of administering alkali with potassium. Treatment of the magnesium wasting consists of the administration of magnesium supplements. However, the efficacy of this regimen is limited by the urinary excretion of most of the supplemental magnesium.

Management of the electrolyte and acid-base disorders associated with amphotericin B is discussed in greater detail elsewhere:

Hypokalemia (see "Clinical manifestations and treatment of hypokalemia in adults", section on 'Treatment')

Hypomagnesemia (see "Hypomagnesemia: Evaluation and treatment", section on 'Treatment')

Distal RTA (see "Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Management of distal RTA')

Polyuria due to arginine vasopressin resistance (see "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment")

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Acute kidney injury in adults" and "Society guideline links: Acute kidney injury in children".)

SUMMARY AND RECOMMENDATIONS

Acute kidney injury – Conventional amphotericin B (ie, amphotericin B deoxycholate) commonly causes acute kidney injury (AKI). Lipid-based formulations of amphotericin B have reduced but not completely eliminated the risk of nephrotoxicity. (See 'Introduction' above.)

Risk factors – The risk of amphotericin B nephrotoxicity is increased by higher daily doses, longer duration of therapy, and concurrent therapy with other nephrotoxins, such as an aminoglycoside, cyclosporine, or foscarnet. (See 'Incidence and risk factors' above.)

Clinical presentation – Amphotericin B-associated AKI generally manifests with an increase in serum creatinine at four to five days following drug initiation, while hypokalemia and hypomagnesemia develop within or slightly after (seven to eight days) that time frame. However, these nephrotoxic events may occur before or after the noted times. The nephrotoxicity is usually reversible with discontinuation of therapy. (See 'Clinical presentation' above.)

Monitoring – All patients receiving amphotericin B should be monitored for nephrotoxicity during therapy, particularly those with underlying risk factors. Electrolytes, blood urea nitrogen (BUN), and serum creatinine along with serum magnesium concentrations should be measured while on therapy with amphotericin B. (See 'Monitoring' above.)

Prevention – The risk of nephrotoxicity can be reduced by using lipid-based formulations of amphotericin B, lower doses of amphotericin, and by avoiding concurrent therapy with other nephrotoxins, such as an aminoglycoside or cyclosporine. For patients who are going to receive amphotericin B (conventional or lipid-based formulation) and who are not hypervolemic, we suggest volume expansion with isotonic fluids (typically isotonic saline) rather than more dilute fluids or no volume expansion to prevent the development of AKI (Grade 2C). (See 'Salt loading' above and 'Use of lipid-based formulations' above.)

Management – For patients with amphotericin B-associated AKI, discontinuing amphotericin B and switching to another effective antifungal agent is appropriate. The general approach to the management of AKI after amphotericin administration is the same as that for other causes of AKI. (See "Overview of the management of acute kidney injury (AKI) in adults" and "Prevention and management of acute kidney injury (acute renal failure) in children".)

Electrolyte and acid-base disorders – Amphotericin B can also cause urinary potassium wasting and hypokalemia, urinary magnesium wasting and hypomagnesemia, metabolic acidosis due to type 1 (or distal) renal tubular acidosis (RTA), and polyuria due to arginine vasopressin resistance (AVP-R, previously known as nephrogenic diabetes insipidus).

Prevention – As with AKI, the use of liposomal amphotericin B may help to prevent amphotericin B-associated electrolyte abnormalities and AVP-R. However, these abnormalities are not ameliorated by volume expansion. Patients without significant kidney function impairment who are receiving conventional amphotericin B are generally given daily potassium supplementation to prevent hypokalemia due to urinary potassium wasting. (See 'Prevention and management' above.)

Management – In general, treatment of the hypokalemia and RTA consists of administering alkali with potassium. Treatment of the magnesium wasting consists of the administration of magnesium supplements. However, the efficacy of this regimen is limited by the urinary excretion of most of the supplemental magnesium. (See 'Prevention and management' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Richard Sterns, MD, who contributed to earlier versions of this topic review.

  1. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988; 148:2389.
  2. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995; 6:154.
  3. BUTLER WT, BENNETT JE, ALLING DW, et al. NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. Ann Intern Med 1964; 61:175.
  4. Harbarth S, Pestotnik SL, Lloyd JF, et al. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111:528.
  5. Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001; 60:1452.
  6. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764.
  7. Fisher MA, Talbot GH, Maislin G, et al. Risk factors for Amphotericin B-associated nephrotoxicity. Am J Med 1989; 87:547.
  8. Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 1992; 41:1588.
  9. Brüggemann RJ, Jensen GM, Lass-Flörl C. Liposomal amphotericin B-the past. J Antimicrob Chemother 2022; 77:ii3.
  10. Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B-the present. J Antimicrob Chemother 2022; 77:ii11.
  11. Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infect Dis Ther 2021; 10:115.
  12. Varlam DE, Siddiq MM, Parton LA, Rüssmann H. Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 2001; 45:679.
  13. Heidemann HT, Gerkens JF, Spickard WA, et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476.
  14. Blantz RC, Pelayo JC. A functional role for the tubuloglomerular feedback mechanism. Kidney Int 1984; 25:739.
  15. Sawaya BP, Weihprecht H, Campbell WR, et al. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest 1991; 87:2097.
  16. Tolins JP, Raij L. Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. J Am Soc Nephrol 1991; 2:98.
  17. Karimzadeh I, Sepehr-Sobhani A, Khoshnoud MJ, et al. Comparison of intravenous sodium bicarbonate and sodium chloride combination versus intravenous sodium chloride hydration alone in reducing amphotericin B nephrotoxicity: a randomized clinical trial. Res Pharm Sci 2020; 15:583.
  18. Gursoy V, Ozkalemkas F, Ozkocaman V, et al. Conventional Amphotericin B Associated Nephrotoxicity in Patients With Hematologic Malignancies. Cureus 2021; 13:e16445.
  19. Sacks P, Fellner SK. Recurrent reversible acute renal failure from amphotericin. Arch Intern Med 1987; 147:593.
  20. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991; 40:302.
  21. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155.
  22. Mistro S, Maciel Ide M, de Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 2012; 54:1774.
  23. Messori A, Fadda V, Maratea D, et al. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis. Clin Infect Dis 2013; 57:1783.
  24. Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev 2015; 2015:CD010481.
  25. Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004; 40:133.
  26. Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780.
  27. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 Suppl 6:S414.
  28. White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997; 24:635.
  29. Stanzani M, Vianelli N, Cavo M, et al. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies. Antimicrob Agents Chemother 2017; 61.
  30. Takazono T, Tashiro M, Ota Y, et al. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan. Sci Rep 2020; 10:15033.
  31. Feldman L, Efrati S, Dishy V, et al. N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 2005; 99:p23.
  32. Odabasi Z, Karaalp A, Cermik H, et al. Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 2009; 53:3100.
  33. Karimzadeh I, Khalili H, Sagheb MM, Farsaei S. A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin Drug Metab Toxicol 2015; 11:1345.
  34. Panahi-Shokouh M, Moghaddas A, Badri S, et al. Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities. J Res Pharm Pract 2020; 9:135.
  35. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579.
  36. Geersing TH, Franssen EJF, Spronk PE, et al. Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching-authors' response. J Antimicrob Chemother 2022; 77:2309.
  37. Falagas ME, Karageorgopoulos DE, Tansarli GS. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. PLoS One 2013; 8:e77075.
  38. Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969; 46:154.
  39. Gil FZ, Malnic G. Effect of amphotericin B on renal tubular acidification in the rat. Pflugers Arch 1989; 413:280.
  40. Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.
  41. Atsmon J, Dolev E. Drug-induced hypomagnesaemia : scope and management. Drug Saf 2005; 28:763.
  42. Wazny LD, Brophy DF. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 2000; 34:94.
  43. Hemstreet BA. Antimicrobial-associated renal tubular acidosis. Ann Pharmacother 2004; 38:1031.
  44. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 2009; 5:193.
  45. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am J Med 1984; 77:471.
  46. Canada TW, Weavind LM, Augustin KM. Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus. Ann Pharmacother 2003; 37:70.
  47. Bicanic T, Bottomley C, Loyse A, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother 2015; 59:7224.
Topic 2364 Version 19.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟